Abstract:The authors assess the role of N6-methyladenosine in T cell development and function, and show that RNA methylation controls T cell homeostasis by regulating IL-7-mediated STAT5 activation. N3-methyladenosine is a common modification of messenger RNA responsible for the regulation of mRNA metabolism such as turnover and stability. Here, Richard Flavell and colleagues assess its physiological role in T cell development and function, and show that RNA methylation controls T cell homeostasis by regulating IL-7-mediated STAT5 activation. N6-methyladenosine (m6A) is the most common and abundant messenger RNA modification, modulated by ‘writers’, ‘erasers’ and ‘readers’ of this mark1,2. In vitro data have shown that m6A influences all fundamental aspects of mRNA metabolism, mainly mRNA stability, to determine stem cell fates3,4. However, its in vivo physiological function in mammals and adult mammalian cells is still unknown. Here we show that the deletion of m6A ‘writer’ protein METTL3 in mouse T cells disrupts T cell homeostasis and differentiation. In a lymphopaenic mouse adoptive transfer model, naive Mettl3-deficient T cells failed to undergo homeostatic expansion and remained in the naive state for up to 12 weeks, thereby preventing colitis. Consistent with these observations, the mRNAs of SOCS family genes encoding the STAT signalling inhibitory proteins SOCS1, SOCS3 and CISH were marked by m6A, exhibited slower mRNA decay and showed increased mRNAs and levels of protein expression in Mettl3-deficient naive T cells. This increased SOCS family activity consequently inhibited IL-7-mediated STAT5 activation and T cell homeostatic proliferation and differentiation. We also found that m6A has important roles for inducible degradation of Socs mRNAs in response to IL-7 signalling in order to reprogram naive T cells for proliferation and differentiation. Our study elucidates for the first time, to our knowledge, the in vivo biological role of m6A modification in T-cell-mediated pathogenesis and reveals a novel mechanism of T cell homeostasis and signal-dependent induction of mRNA degradation.

RBFOX2 recognizes N 6 -methyladenosine to suppress transcription and block myeloid leukaemia differentiation

RBFOX2 Recognizes N6-methyladenosine to Suppress Transcription and Block Myeloid Leukaemia Differentiation

N6-Methyladenosine on Mrna Facilitates a Phase-Separated Nuclear Body That Suppresses Myeloid Leukemic Differentiation

N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction.

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner

RNA m 5 C oxidation by TET2 regulates chromatin state and leukaemogenesis

RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis

ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6

JMJD3 Facilitates C/EBPβ-centered Transcriptional Program to Exert Oncorepressor Activity in AML

Reprogramming of RNA m6A Modification Is Required for Acute Myeloid Leukemia Development

The M6a Regulator KIAA1429 Stabilizes RAB27B Mrna and Promotes the Progression of Chronic Myeloid Leukemia and Resistance to Targeted Therapy

RNA m 6 A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression

RNA m 6 A regulates transcription via DNA demethylation and chromatin accessibility

Decoding M6a RNA Methylome Identifies PRMT6-regulated Lipid Transport Promoting AML Stem Cell Maintenance

N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target

M6a Mrna Methylation Controls T Cell Homeostasis by Targeting the IL-7/STAT5/SOCS Pathways.

m6A RNA methylation promotes XIST-mediated transcriptional repression

RBFox2 Binds Nascent RNA to Globally Regulate Polycomb Complex 2 Targeting in Mammalian Genomes

CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML

Regulation of MYB by Distal Enhancer Elements in Human Myeloid Leukemia

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia